



# BLISS GVS PHARMA LIMITED

Registered Office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400 072.

## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2013

PART - I		(RS. in Lakhs)					
SR. No.	PARTICULARS	STANDALONE					
		QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2013 (UNAUDITED)	30.09.2013 (UNAUDITED)	31.12.2012 (UNAUDITED)	31.12.2013 (UNAUDITED)	31.12.2012 (UNAUDITED)	31.03.2013 (AUDITED)
1	Income From Operations						
	(a) Net Sales (Net of Excise Duty)	5885.77	9718.60	8131.69	22976.12	24798.11	34810.82
	(b) Other Operating Income	114.98	219.69	105.24	520.59	451.82	557.50
	<b>Total Income From Operations (Net)</b>	<b>6000.75</b>	<b>9938.29</b>	<b>8236.93</b>	<b>23496.71</b>	<b>25249.93</b>	<b>35368.32</b>
2	Expenses						
	A) Consumption of Raw Materials	2221.23	4957.68	4,573.28	10,615.19	13,275.61	18849.51
	B) Purchase of Traded Goods	0.00	341.43	0.00	500.90	307.77	360.28
	C) Changes in inventories of finished goods, work in progress, Stock in Trade	165.13	-241.82	-440.06	429.95	-417.08	-511.73
	D) Employee Benefit Expenses	323.94	335.28	282.42	952.13	714.17	987.07
	E) Depreciation / Amortisation	128.04	141.57	105.86	374.59	323.07	442.78
	F) Other Expenditure	1355.59	1686.29	1324.30	4883.16	2947.63	5604.99
	<b>Total Expenses</b>	<b>4193.93</b>	<b>7220.43</b>	<b>5845.80</b>	<b>17755.92</b>	<b>17151.17</b>	<b>25732.90</b>
3	<b>Profit From Operations Before Other Income &amp; Finance Cost &amp; Exceptional Items (1-2)</b>	<b>1806.82</b>	<b>2717.86</b>	<b>2391.13</b>	<b>5740.79</b>	<b>8098.76</b>	<b>9635.42</b>
4	Other Income	145.46	936.78	225.65	2699.80	626.44	1503.28
5	<b>Profit From Ordinary Activities Before Finance Cost (3+4)</b>	<b>1952.28</b>	<b>3654.64</b>	<b>2616.78</b>	<b>8440.59</b>	<b>8725.20</b>	<b>11138.70</b>
6	Finance Cost	220.86	224.63	196.87	634.19	381.68	655.47
7	<b>Profit From Ordinary Activities After Finance Cost But Before Exceptional Items (5-6)</b>	<b>1731.42</b>	<b>3430.01</b>	<b>2419.91</b>	<b>7806.40</b>	<b>8343.52</b>	<b>10483.23</b>
8	Exceptional Items	-	-	-	-	-	-
9	<b>Profit From Ordinary Activities Before Tax (7-8)</b>	<b>1731.42</b>	<b>3430.01</b>	<b>2419.91</b>	<b>7806.40</b>	<b>8343.52</b>	<b>10483.23</b>
10	Tax Expense (including Deferred Tax)	668.58	1076.67	1481.02	2565.19	3245.74	4815.03
11	<b>Net Profit After Tax For The Period (9 - 10)</b>	<b>1062.84</b>	<b>2353.34</b>	<b>938.89</b>	<b>5241.21</b>	<b>5097.78</b>	<b>5668.20</b>
12	Paid - Up Equity Capital	1031.47	1031.47	1031.47	1031.47	1031.47	1031.47
13	Reserves Excluding Revaluation Reserve (as Per Balance Sheet)	-	-	-	-	-	24842.03
14	<b>Basic and Diluted Eps (not Annualised)</b>	<b>1.03</b>	<b>2.28</b>	<b>0.91</b>	<b>5.08</b>	<b>4.94</b>	<b>5.50</b>
PART - II							
A	Particulars of Shareholding						
1	Aggregate of Non-promoter Shareholding						
	- No. of Shares (Face Value Rs.1/- Each)	36156842	36156842	36187842	36156842	36187842	36186842
	- Percentage of Shareholding (%)	35.05	35.05	35.08	35.05	35.08	35.08
2	Promoter and Promoter Group Shareholding						
	A) Pledge/ Encumbered						
	- No. of Shares (Face Value Re.1/- Each)	-	-	-	-	-	-
	- Percentage of Shares (As % of the total Share Holding of Promoter & Promoter Group)	-	-	-	-	-	-
	- Percentage of Shares (As % of the total Share Capital of The Company)	-	-	-	-	-	-
	B) Non - Encumbered						
	- No. of Shares (Face Value Re.1/- Each)	66989830	66989830	66958830	66989830	66958830	66959830
	- Percentage of Shares (As % of the total Share Holding of Promoter & Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (As % of the total Share Capital of The Company)	64.95	64.95	64.92	64.95	64.92	64.92
PARTICULARS		Quarter ended 31 DECEMBER 2013					
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter				-		
	Received during the quarter				5		
	Disposed off during the quarter				5		
	REMAINING UNSOLVED AT THE END OF THE QUARTER				-		

Notes:-

- The company operates primarily in the pharmaceutical business and hence has only one reportable segment.
- The statutory auditors have carried out "limited review" of the aforesaid results.
- The above results were reviewed by the audit committee & were there after approved by the board at its meeting held on February 12, 2014
- Other Income for Nine Months Ended 31st December 2013 includes realised exchange gain of Rs. 1211.51 lacs (Previous Nine Months Ended Rs. 693.36 lacs) and unrealised exchange gain (Net) of Rs. 951.81 lacs. (Previous Nine Months Ended Rs. -491.85 lacs)
- Figures for the Previous year / Quarters have been regrouped/rearranged wherever necessary.

FOR BLISS GVS PHARMA LIMITED

SD/-

S. N. KAMATH  
MANAGING DIRECTOR

Place : Mumbai  
Date : 12-02-2014

**Head Office : Mumbai**

- Tel : (022) 2200 0607 / 7318 / 6360  
(022) 6631 5835 / 36
- Fax : (022) 2200 3476
- E-mail : info@bkkhareco.com
- 706 / 708, Sharda Chambers,  
New Marine Lines, Mumbai 400 020

**B. K. KHARE & Co.**  
CHARTERED ACCOUNTANTS

Limited Review Report


The Board of Directors  
Bliss GVS Pharma Limited  
Mumbai

We have reviewed the accompanying Statement of unaudited financial results of Bliss GVS Pharma Limited for the period ended December 31, 2013 ("the Statement") except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding', which have been traced from disclosures, made by the management and have not been audited by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the Accounting Standards notified under the Companies Act, 1956 read with the General Circular 15/2013 dated September 13, 2013 of the Ministry of Corporate Affairs in respect of Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B. K. Khare & Co.  
Chartered Accountants  
Firm Registration No. 105102W



Devdatta Mainkar  
Partner  
Membership No. 109795

Place: Mumbai  
Date: February 12, 2014



**Branch Office : Pune**

- Tel : (020) 64019743 / 25666932 / 32926341
- E-mail : pune@bkkhareco.com
- Hotel Swaroop, 4<sup>th</sup> Floor, Lane No. 10,

**Branch Office : Bengaluru**

- Tel : (080) 4110 5357 •
- E-mail : bkkhareb@vsnl.net •
- 101, Money Chambers, 1<sup>st</sup> Floor •
- #6 K. H. Road, Shanthinagar, Bengaluru - 560027